News & Updates

Interleukin-17 inhibition with the biologic disease-modifying antirheumatic drug (DMARD) secukinumab appears to produce a substantial reduction in synovitis in psoriatic arthritis, in addition to improvements in the signs and symptoms of the disease, according to the results of the phase III ULTIMATE.

A modified dual therapy as first-line treatment for H. pylori infection demonstrates equal efficacy and compliance relative to recommended regimens, reveals a study. Moreover, a generally modified dual therapy has fewer side effects.

Dietary intake of alpha linolenic acid (ALA) appears to reduce the risk of mortality from all causes, cardiovascular disease (CVD), and coronary heart disease (CHD) but may slightly increase the risk of cancer mortality, according to a systematic review and meta-analysis. Moreover, an association exists between higher blood levels of ALA and a lower risk of all-cause and CHD mortality.

A healthier overall diet score and higher fibre, fruit, and vegetable scores result in better health outcomes in adults with multiple sclerosis (MS), according to a study, noting a much lower proportion of participants avoiding dairy and meat or adhering to a specific MS diet than previously reported.

Though promising, coronavirus disease 2019 (COVID-19) symptom checkers—online, patient-led triage systems—are unable to reliably distinguish mild from severe COVID-19 and may instead put the public and healthcare workers at greater risk of infection, according to a recent study.

Type 2 diabetes (T2D) patients who are taking multiple medications together are at heightened risk of bone fractures, a study has found.

Patients with kidney disease appear to have a slightly elevated risk of dementia, which is driven by vascular dementia, a study suggests.

In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression ≥1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.